Ozempic Alternatives Compared

The right Ozempic alternative depends on why Ozempic isn't working for you. If the problem is cost or insurance, the fix is often a different brand that your plan or a self-pay program covers. If you want more weight loss, tirzepatide (Zepbound or Mounjaro) has beaten semaglutide head to head. If you hate needles, there are now three FDA-approved GLP-1 pills. And if you're tempted by retatrutide or cheap online "semaglutide," read the warnings below before you spend a dollar.

This guide was updated in October 2026, after a busy year: Rybelsus became Ozempic tablets, Foundayo (orforglipron) was approved, the Wegovy pill launched, and Medicare started a $50 GLP-1 program that covers some of these drugs but not Ozempic. Here's how the options actually compare.

Most people who ask about alternatives aren't unhappy with semaglutide itself. They're stuck on price, coverage, side effects, or the shot. Each of those problems points to a different answer, so it's worth naming yours before you compare drug names.

Prices below are the lowest advertised self-pay starting prices as of October 2026. They apply to the starting dose, and most people pay more once they reach a maintenance dose. Insurance pricing is a separate world; see our Ozempic cost guide for the full picture.

Wegovy is semaglutide, exactly like Ozempic. The difference is the label: Ozempic is approved for type 2 diabetes, while Wegovy is approved for chronic weight management and goes up to a higher weekly dose (2.4 mg versus Ozempic's 2 mg maximum). That label difference matters more than people expect, because insurers decide coverage by diagnosis, not by molecule.

If you don't have type 2 diabetes and you're paying out of pocket for Ozempic, Wegovy is usually the more logical choice. It's also one of the drugs covered by Medicare's GLP-1 Bridge for eligible weight-management patients, which Ozempic is not. There is also now a daily Wegovy pill, covered in the pills section below. For a deeper comparison, see Ozempic vs Wegovy.

Tirzepatide is a different molecule. It activates two hormone receptors (GIP and GLP-1) instead of one, and it's sold as Mounjaro for type 2 diabetes and Zepbound for weight management and obstructive sleep apnea in people with obesity. Same drug, two labels, the same split as Ozempic and Wegovy.

This is the one comparison where we have a clean head-to-head answer. In the SURMOUNT-5 trial, published in the New England Journal of Medicine, adults with obesity and without diabetes lost an average of 20.2% of body weight on tirzepatide versus 13.7% on semaglutide after 72 weeks. Stomach side effects led to stopping treatment slightly more often in the semaglutide group.

That doesn't make tirzepatide the automatic winner for everyone. Some people do very well on semaglutide and see no reason to switch, and coverage often decides the question before efficacy does. But if you've been on a full maintenance dose of semaglutide for several months and progress has stalled, tirzepatide is the most evidence-backed next step to discuss.

A year ago, "GLP-1 pill" meant Rybelsus. In 2026 there are three different pills, and the practical difference between them is bigger than the marketing suggests.

That last point is the one patients actually feel day to day. Oral semaglutide only absorbs well on an empty stomach, so both semaglutide pills come with a morning routine: take it first thing with a small sip of water, then wait before eating, drinking coffee or taking other pills. People who travel, work night shifts, or take several morning medications often find this harder than a weekly shot. Foundayo can be taken any time of day, with or without food.

On results, the pills land below the strongest injections. In trials, the highest Foundayo dose produced about 12.4% average weight loss, and the Wegovy pill about 16.6% at 64 weeks. That's meaningful, but if maximum weight loss is your goal, an injection still has the edge.

Trulicity (dulaglutide) is another weekly GLP-1 injection for type 2 diabetes. It's often on formularies that exclude newer drugs, which is the main reason people end up on it. It generally lowers weight less than semaglutide and isn't approved for weight loss.

Liraglutide (Victoza for diabetes, Saxenda for weight management) is a daily injection, and generic versions are now sold in U.S. pharmacies. Daily dosing and smaller average weight loss are the trade-offs, but the lower price makes it worth asking about if nothing else is covered.

Metformin isn't a GLP-1 at all. It's an inexpensive first-line diabetes pill with a long safety record and, at most, modest effects on weight. It's a sensible part of many diabetes plans, but it isn't a cheaper version of Ozempic, and anyone selling it that way is overselling it.

During the shortage years, compounded semaglutide filled the gap. That window closed when FDA declared the semaglutide shortage over in February 2025, and the rules for copying brand-name GLP-1s tightened after that. FDA has also said that salt forms such as semaglutide sodium and semaglutide acetate are not the same active ingredient as in approved products and shouldn't be used for compounding.

If someone offers you compounded semaglutide today, ask three questions: which licensed pharmacy made it, what exactly is the active ingredient, and how is the dose measured. FDA has documented overdoses from people misreading doses drawn from multi-dose vials. Our compounded semaglutide guide covers the details, and FDA keeps an updated page on unapproved GLP-1 drugs.

Retatrutide is Lilly's experimental triple-hormone drug, and its trial results have been striking. It is still not approved. Lilly has said it plans to submit it to FDA in the first quarter of 2027, so any approval is unlikely before then.

Here's the practical part: FDA has stated that retatrutide cannot be used in compounding, and it has warned telehealth companies and ingredient suppliers selling it. Anything sold online as retatrutide right now, including vials labeled "for research use only," is not a legitimate product. No dose, purity or sterility is guaranteed.

Switching is not a straight swap. When people move from semaglutide to tirzepatide or to a pill, prescribers usually start the new drug at a lower dose and step up again, which can mean several weeks of the same nausea and appetite changes you had at the beginning. Weight loss can also slow while you climb back up.

For the most common head-to-head question, whether tirzepatide beats semaglutide and by how much, see Ozempic vs Mounjaro, which lays out the SURPASS-2 numbers dose by dose and explains how switching works.

For weight loss without diabetes, Wegovy, Zepbound and Foundayo are the approved choices, and they're also the ones Medicare's weight-loss program covers. For the most weight loss, tirzepatide has the strongest head-to-head data. For no needles, pick between the semaglutide pills and Foundayo based on whether you can live with the empty-stomach routine. For type 2 diabetes, the list is longer and more flexible, from Ozempic tablets and Mounjaro to Trulicity, liraglutide and metformin.

And for retatrutide and gray-market "semaglutide," the honest answer is to wait. A legitimate option at a slightly higher price is still a better deal than a vial with an unknown dose.